NCT04429542 - Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors | Biotech Hunter

Enrollment

292

Participants

Timeline

Start Date

June 1, 2020

Primary Completion Date

December 31, 2026

Study Completion Date

June 1, 2027

Conditions

Head and Neck Squamous Cell CarcinomaSquamous Cell Carcinoma of Anal CanalColorectal CancerSquamous Cell Carcinoma of the LungEGFR AmplificationEpithelial Ovarian CancerPancreas CancerCutaneous Squamous Cell CarcinomaHead and Neck NeoplasmsCarcinoma, Squamous CellSquamous Cell Carcinoma of Head and Neck

Interventions

DRUG

BCA101

EGFR/TGFβ fusion monoclonal antibody

DRUG

Pembrolizumab

anti-PD-1

Trial Locations (20)

2050

RECRUITING

Chris O'Brien Lifehouse, Camperdown

2298

RECRUITING

Calvary Mater Newcastle, Waratah

3000

RECRUITING

Peter MacCallum Cancer Centre, Melbourne

3084

RECRUITING

Austin Hospital, Heidelberg

10017

RECRUITING

Memorial Sloan Kettering, New York

10032

RECRUITING

Columbia University Herbert Irving Comprehensive Cancer Center, New York

15232

RECRUITING

UPMC Hillman Cancer Center, Pittsburgh

28204

RECRUITING

Levine Cancer Institute, Charlotte

29425

RECRUITING

Medical University of South Carolina, Hollings Cancer Center, Charleston

33612

RECRUITING

H. Lee Moffitt Cancer Center and Research Institute, Inc, Tampa

37232

RECRUITING

Vanderbilt University Medical Center, Nashville

44195

RECRUITING

Cleveland Clinic, Cleveland

77030

RECRUITING

MD Anderson Cancer Center, Houston

90033

RECRUITING

Keck School of Medicine of USC, Los Angeles

90095

RECRUITING

UCLA, Los Angeles

92093

RECRUITING

Moores Cancer Center UC San Diego Health, La Jolla

95817

RECRUITING

University of California, Davis Comprehensive Cancer Center, Sacramento

02115

RECRUITING

Dana Farber/Partners Cancer Care Inc, Boston

02903

RECRUITING

Rhode Island Hospital, Providence

M5G 2M9

RECRUITING

Princess Margaret Cancer Centre, Toronto